MRKR

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

Wall Street analysts forecast MRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRKR is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Marker Therapeutics Inc revenue for the last quarter amounts to 1.23M USD, decreased -35.99 % YoY.

Marker Therapeutics Inc. EPS for the last quarter amounts to -0.12 USD, decreased -53.85 % YoY.

Marker Therapeutics Inc (MRKR) has 5 emplpoyees as of January 09 2026.

Today MRKR has the market capitalization of 34.51M USD.